***Semiannual Meeting***

 *Friday, May 31, 2024 7:30 am-12:00 pm Central Time*

*Hyatt Centric Chicago Magnificent Mile (Grand Ballroom)*

|  |  |
| --- | --- |
| **7:30 am** | **Breakfast** |
| **8:00-8:20** | **SARC Clinical & Science Initiatives** |
| **Upcoming events & collaborative opportunities** | **Chappie Conrad MD** (SARC Board Chair; UT Houston)**Jonathan Fletcher MD** (SARC CSO; Harvard U.)**Scott Okuno MD** (SARC CMO; Mayo Clinic)**Steven Young** (SARC President & CEO) |
| **8:20-9:50** | **Targeting DDR and Genomic Integrity in Sarcoma** |
| **Introductions by Moderators** | **Jonathan Fletcher MD****Rebecca Gladdy MD PhD** (U. of Toronto) |
| **Manipulating DDR protein localization: Tx strategies** | **David Loeb MD PhD** (Albert Einstein College of Medicine) |
| **Precision oncology in osteosarcoma** | **Katie Janeway MD** (Dana-Farber Cancer Institute) |
| **SARC032: RT/I-O for extremity sarcoma – What have we learned?** | **David Kirsch MD PhD** (Princess Margaret Cancer Centre, UHN) |
| **Discussion** |  |
| **9:50-10:20** | **Break (30 minutes)** |
| **10:20-11:20** | **SARC028: Lessons Learned/Paths Forward** |
| **Introductions****Moderator/Coordinator** | **Scott Okuno MD****Sandra D’Angelo MD** (Memorial Sloan Kettering Cancer Institute) |
| **SARC 028: Development and Results** | **Melissa “Missy” Burgess MD** (U. of Pittsburgh Medical Center) |
| **TLS as a Predictor biomarker****Proponents:****Against:** | **Florent Petitprez PhD** (U. of Edinburgh)&**Emily Z. Keung MD** (MD Anderson Cancer Center)**Breelyn Wilky MD** (U. of Colorado) |
| **Discussion** |  |
| **11:20-11:45** | **Career Awardee Presentation** |
| **Androgen receptor targeting in DSRCT** | **Danh Truong PhD** (MD Anderson Cancer Center) |
| **11:45-12:00** | **SARC-Sponsored Clinical Trials** | **Presenter (bolded)** |
| **Introductions** | **Scott Okuno MD** |
| **SARC037 Phase I/II Trabectedin in Ewing Sarcoma in Combination with Irinotecan & 18F-FLT Imaging** | **Patrick Grohar MD PhD** (Children’s Hospital of Philadelphia) |
| **SARC041 Phase III Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS**  | **Mark Dickson MD** (Memorial Sloan Kettering Cancer Institute) |
| **SARC044 Phase II Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST who Progressed on Sunitinib Monotherapy** | **Candace Haddox MD** (Dana-Farber Cancer Institute) |
| **12:00 noon Closing Comments & Adjourn** |  |